XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 29.37

+8.3%

Jan 14 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LarryS who wrote (3746)	9/14/1997 8:35:00 PM
From: Turbo Lawyer	of 17367

re: Newsletters, what are everyone's opinions on the Medical Tech Stock Newsletter. Is Jim McCamant's reputation good? I received written permission from the MTSN to post an excerpt from their July 31 edition: JULY 31, 1997: "Xoma has received four more patents related to their BPI product platform, bringing the total number issued patents related to BPI-derived products to 22. They have also have seven notices of allowances and 20 more pending patent applications. XOMA continues o increase the protection of their efforts in this area, as they have consistently increased their patent position over the last several years. We spoke with the company recently, and learned they they will be meeting with the FDA to discuss the Phase II trial results of Neuprex in the hemorrhagic trauma indication. They will also discuss protocol for the impending Phase III trial, which XOMA hopes to begin by Labor Day. In addition, the safety monitoring committee will be receiving data on the first 65 kids in the Phase III trial for meningococcemia in mied-September. There is some possibility that the date will be so good that they will stop the trial at this point and file for approval based upon that data. The company is also in active discussions with potential partners. It is our sense that the recent strength is a result of inte4st picking up on the group, as well as excitement about developments that will take place during the rest of the years. XOMA is a buy under $8. AUG 4 Rec: "Immediate Buy" AUG 13: "Model Portfolio" - "XOMA will be reporting earnings this week. The stock has moved up as they did okay in their FDA meeting this week and shuld be abel to move into Phase III by September" AUG 18: "Model Portfolio" SEPT 3: "Model Port" - "VICL, XOMA and ISNV are all attractive right now." SEPT: 8: "Model Port" ( = I also received permission from Independent Investors Digest [iidigest@aol.com] to post their overview of MTLS's overview of XOMA, that is where I got the Aug 4 through Sept. through 8 recommendations)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next